Biomedal

Biomedal Life Science is devoted to the development and commercialization of products and services for life sciences research, and technology for industrial bioprocesses. Its own technology allowed the improvement of recombinant protein production.Biomedal Life Science also functions as a CRO (Contract Research Organization) and provides services and support to pharmaceutical or biotechnology companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

news image

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More

MEDTECH

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche | January 25, 2021

news image

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

news image

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

news image

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More
news image

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More
news image

MEDTECH

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche | January 25, 2021

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More
news image

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More
news image

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More